Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

Condensed Interim Consolidated Statements of Cash Flows (Unaudited)

v3.21.1
Condensed Interim Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Operating    
Net loss $ (14,794) $ (768)
Non-cash items    
Depreciation of right-of-use assets 54 14
Amortization of patents 12
Depreciation of property, plant and equipment 31
Interest expense on lease liabilities 14
Stock-based compensation expense 769 229
Loss (gain) on change in fair value of warrants 3,054 (1,168)
Non-cash issue costs 26
Non-cash settlement included in payables 251
Accrued interest on Note payable 37
Prepaid expenses and deposits (981) 173
Accounts payable and accrued liabilities (1,506) (1,228)
Cash used in operating activities (13,310) (2,471)
Financing    
Exercise of Derivative warrants 8,000
January 2021 Equity Offering, net of issuance costs 10,231
February 2021 Equity Offering, net of issuance costs 21,093
Exercise of Equity warrants 1,985
Exercise of stock options 14
Net proceeds from issuance of common shares 3,477
Note payable 122
Repayment of lease liabilities (44) (4)
Cash provided by financing activities 41,401 3,473
Investing    
Purchase of property, plant and equipment (93)
Purchase of patents (97) (56)
Cash used in investing activities (190) (56)
Increase in cash and cash equivalents 27,901 946
Cash and cash equivalents, beginning of the period 25,469 814
Cash and cash equivalents, end of the period $ 53,370 $ 1,760